PetVivo CEO Discusses Breakthrough Regenerative Medicine Acquisition

Jun 25, 2026

PetVivo Holdings (NASDAQ: PETV) CEO John Lai discusses the company’s acquisition of Piezo Biomembrane, a University of Connecticut spinout developing advanced nanofiber and piezoelectric technologies. The merger combines Piezo’s biomaterial platform with PetVivo’s Spryng™ technology to create regenerative therapies designed to help repair cartilage, restore tissue, and accelerate healing in both veterinary and human medicine.

Lai explains how the combined technology could expand into applications including osteoarthritis treatment, wound care, diabetic ulcers, and regenerative joint therapies, while supporting future FDA human clinical trials. The company expects to complete large animal studies before advancing toward human studies, with the long-term goal of delivering cost-effective regenerative treatments that improve patient outcomes and reduce the need for invasive procedures such as joint replacements.

#PetVivo
#PETV
#RegenerativeMedicine
#Biotechnology
#MedicalDevices
#Osteoarthritis
#JointHealth
#CartilageRepair
#VeterinaryMedicine
#HealthcareInnovation
#BiomedicalEngineering
#FDA
#NASDAQ
#JaneKing
#NewsOut